This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the official electronic version on GPO’s govinfo.gov.
The documents posted on this site are XML renditions of published Federal Register documents. Each document posted on the site includes a link to the corresponding official PDF file on govinfo.gov. This prototype edition of the daily Federal Register on FederalRegister.gov will remain an unofficial informational resource until the Administrative Committee of the Federal Register (ACFR) issues a regulation granting it official legal status. For complete information about, and access to, our official publications and services, go to About the Federal Register on NARA's archives.gov.
The OFR/GPO partnership is committed to presenting accurate and reliable regulatory information on FederalRegister.gov with the objective of establishing the XML-based Federal Register as an ACFR-sanctioned publication in the future. While every effort has been made to ensure that the material on FederalRegister.gov is accurately displayed, consistent with the official SGML-based PDF version on govinfo.gov, those relying on it for legal research should verify their results against an official edition of the Federal Register. Until the ACFR grants it official status, the XML rendition of the daily Federal Register on FederalRegister.gov does not provide legal notice to the public or judicial notice to the courts.
FederalRegister.gov retrieves relevant information about this document from Regulations.gov to provide users with additional context. This information is not part of the official Federal Register document.
Food and Drug Administration, HHS.
Final rule; technical amendment.
In the Federal Register of July 25, 2001 (66 FR 38786), the Food and Drug Administration (FDA) amended its medical device classification regulations for class I devices to specifically add a reference to the general limitations on exemptions from premarket notification requirements from each generic device classified as exempt in each section. As published, an exemption from the premarket notification requirements and a reference to the general limitations language was inadvertently added to 12 device classifications that should not include the reference. These devices are not exempt from the requirements of premarket notification. This document corrects those errors.
This rule is effective September 10, 2001.
Heather S. Rosecrans, Center for Devices and Radiological Health (HFZ-404), 9200 Corporate Blvd., Rockville, MD 20850, 301-594-1190.
( printed page 46952)Provisions under section 206 of the Food and Drug Administration Modernization Act (FDAMA) exempt certain class I devices from the premarket notification requirements of the Federal Food, Drug, and Cosmetic Act (the act). To implement the new law, FDA evaluated all class I devices to determine which device types should become exempt under the new provisions and which device types should remain subject to the requirements of 510(k) of the act (21 U.S.C. 360(k)). FDA then amended its classification regulations through a series of publications in the Federal Register (63 FR 63222, November 12, 1998; 65 FR 2296, January 14, 2000; 63 FR 5387, February 2, 1998; and 66 FR 38786). The most recent amendment (66 FR 38786) revised statutory citations for over 500 devices in order to reference the limitation provisions found in each device classification regulation for devices that were exempt from the premarket notification requirements for clarity and convenience. During preparation of the final rule, however, certain devices were inadvertently included in a list of devices to be amended, and were erroneously changed by adding the limitations language and an exemption from premarket notification. This document corrects those errors.
The agency has determined under 21 CFR 25.30(h) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.
FDA has examined the impact of this rule under Executive Order 12866 and the Regulatory Flexibility Act (5 U.S.C. 601-612) (as amended by subtitle D of the Small Business Regulatory Fairness Act of 1996 (Public Law 104-121)), and the Unfunded Mandates Reform Act of 1995 (Public Law 104-4). Executive Order 12866 directs agencies to assess all costs and benefits of available regulatory alternatives and, when regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, environmental, public health and safety, and other advantages; distributive impacts; and equity). The agency believes that this rule is consistent with the regulatory philosophy and principles identified in the Executive order. In addition, this rule is not a significant regulatory action as defined by the Executive order and so is not subject to review under the Executive order.
The Regulatory Flexibility Act requires agencies to analyze regulatory options that would minimize any significant impact of a rule on small entities. Because this rule does not change the status quo for these devices, the agency certifies that this final rule will not have a significant negative economic impact on a substantial number of small entities. Section 202(a) of the Unfunded Mandates Reform Act of 1995 (Public Law 104-4) requires that agencies prepare a written statement of anticipated costs and benefits before proposing any rule that may result in an expenditure by State, local, and tribal governments, in the aggregate, or by the private sector, of $100 million in any one year (adjusted annually for inflation). The Unfunded Mandates Reform Act does not require FDA to prepare a statement of costs and benefits for the final rule, because the final rule is not expected to result in any 1-year expenditure that would exceed $100 million.
This final rule contains no collections of information. Therefore, clearance by the Office of Management and Budget under the Paperwork Reduction Act of 1995 is not required.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR parts 872, 878, 880, 882, 884, and 892 are amended as follows:
1. The authority citation for 21 CFR part 872 continues to read as follows:
2. Section 872.6710 is amended by revising paragraph (b) to read as follows:
(b) Classification. Class I (general controls).
3. The authority citation for 21 CFR part 878 continues to read as follows:
4. Section 878.4460 is amended by revising paragraph (b) to read as follows:
(b) Classification. Class I (general controls).
5. The authority citation for 21 CFR part 880 continues to read as follows:
6. Section 880.5680 is amended by revising paragraph (b) to read as follows:
(b) Classification. Class I (general controls). The device is exempt from the good manufacturing practice regulation in part 820 of this chapter, with the exception of § 820.180, with respect to general requirements concerning records, and § 820.198, with respect to complaint files.
7. Section 880.6250 is amended by revising paragraph (b) to read as follows:
(b) Classification. Class I (general controls).
8. Section 880.6375 is amended by revising paragraph (b) to read as follows:
(b) Classification. Class I (general controls).
9. Section 880.6760 is amended by revising paragraph (b) to read as follows:
(b) Classification. Class I (general controls).
10. The authority citation for 21 CFR part 882 continues to read as follows:
11. Section 882.1030 is amended by revising paragraph (b) to read as follows:
(b) Classification. Class I (general controls).
( printed page 46953)12. Section 882.1420 is amended by revising paragraph (b) to read as follows:
(b) Classification. Class I (general controls).
13. The authority citation for 21 CFR part 884 continues to read as follows:
14. Section 884.2980 is amended by revising paragraph (a)(2) to read as follows:
(a) * * *
(2) Classification. Class I (general controls).
15. Section 884.2982 is amended by revising paragraph (a)(2) to read as follows:
(a) * * *
(2) Classification. Class I (general controls).
16. The authority citation for 21 CFR part 892 continues to read as follows:
17. Section 892.1100 is amended by revising paragraph (b) to read as follows:
(b) Classification. Class I (general controls).
18. Section 892.1110 is amended by revising paragraph (b) to read as follows:
(b) Classification. Class I (general controls).
Dated: August 23, 2001.
Linda S. Kahan,
Deputy Director, Center for Devices and Radiological Health.
[FR Doc. 01-22577 Filed 9-7-01; 8:45 am]
BILLING CODE 4160-01-S